Ranibizumab
| Monoclonal antibody | |
|---|---|
| Type | Fab fragment |
| Source | Humanized (from mouse) |
| Target | VEGF-A |
| Clinical data | |
| Trade names | Lucentis |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607044 |
| License data | |
| Pregnancy category |
|
| Routes of administration |
Intravitreal injection |
| ATC code | S01LA04 (WHO) |
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Biological half-life | Approx. 9 days |
| Identifiers | |
| CAS Number |
347396-82-1 
|
| DrugBank |
DB01270
|
| ChemSpider | none |
| UNII |
ZL1R02VT79
|
| KEGG |
D05697 
|
| ChEMBL |
CHEMBL1201825
|
| Chemical and physical data | |
| Formula | C2158H3282N562O681S12 |
| Molar mass | 48,350 g/mol |
|
(what is this?)
|
|
Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss.
Its effectiveness is similar to that of bevacizumab. Its rates of side effects also appear similar. However, ranibizumab typically costs $2,000 a dose, while the equivalent dose of bevacizumab typically costs $50.
Ranibizumab was developed by Genentech and is marketed in the United States by Genentech and elsewhere by Novartis, under the brand name Lucentis.
Ranibizumab is a monoclonal antibody that inhibits angiogenesis by inhibiting Vascular endothelial growth factor A, a mechanism similar to Bevacizumab.
It is often used for age-related wet macular degeneration. Its effectiveness is similar to that of bevacizumab and aflibercept.
A 2014 Cochrane review did not find a difference between bevacizumab and ranibizumab in deaths or total severe side effects when used for macular degeneration. There; however, was not a lot of evidence and thus this conclusion is not that certain.
Ranibizumab does appear to result in a lower risk of stomach and intestinal problems. It is also associated with a low rate of eye related side effects.
The most common side effects in clinical trials were conjunctival haemorrhage, eye pain, vitreous floaters, increased intraocular pressure, and intraocular inflammation.
...
Wikipedia